Preserving Residual Renal Function in Dialysis: What We Know

Seminars in Dialysis

Volumn 28, Issue 3, 2015, Pages 250-258

  Patel, Nikunjkumar ^a   Hu, Susie L ^a  

^a BROWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLOMERULUS FILTRATION RATE; HEMODIALYSIS; HUMAN; KIDNEY; KIDNEY FAILURE, CHRONIC; PHYSIOLOGY; PROCEDURES;

GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY; KIDNEY FAILURE, CHRONIC; RENAL DIALYSIS;

EID: 84929606545     PISSN: 08940959     EISSN: 1525139X     Source Type: Journal    
DOI: 10.1111/sdi.12302     Document Type: Article

References (87)

1. Bargman JM, Thorpe KE, Churchill DN, Group CPDS: Relative contribution of residual renal function and peritoneal clearance to adequacy of dialysis: a reanalysis of the CANUSA study. J Am Soc Nephrol 12: 2158-2162, 2001
2. Paniagua RN, Vonesh E, Correa-Rotter R, Ramos A, Moran J, Mujais S: Group ftMNCS: Effects of increased peritoneal clearances on mortality rates in peritoneal dialysis: ADEMEX, a prospective, randomized, controlled trial. J Am Soc Nephrol 13:1307-1320, 2002
3. Shafi T, Jaar BG, Plantinga LC, Fink NE, Sadler JH, Parekh RS, Powe NR, Coresh J: Association of residual urine output with mortality, quality of life, and inflammation in incident hemodialysis patients: the Choices for Healthy Outcomes in Caring for End-Stage Renal Disease (CHOICE) Study. Am J Kidney Dis 56:348-358, 2010
4. Perl J, Huckvale K, Chellar M, John B, Davies SJ: Peritoneal protein clearance and not peritoneal membrane transport status predicts survival in a contemporary cohort of peritoneal dialysis patients. Clin J Am Soc Nephrol 4:1201-1206, 2009
5. Moist LM, Port FK, Orzol SM, Young EW, Ostbye T, Wolfe RA, Hulbert-Shearon T, Jones CA, Bloembergen WE: Predictors of loss of residual renal function among new dialysis patients. J Am Soc Nephrol 11:556-564, 2000
6. Jansen MA, Hart AA, Korevaar JC, Dekker FW, Boeschoten EW, Krediet RT, Group NS: Predictors of the rate of decline of residual renal function in incident dialysis patients. Kidney Int 62: 1046-1053, 2002
7. Lang SM, Bergner A, Topfer M, Schiffl H: Preservation of residual renal function in dialysis patients: effects of dialysis-technique-related factors. Perit Dial Int 21:52-57, 2001
8. Kuriyama S: Peritoneal dialysis in patients with diabetes: are the benefits greater than the disadvantages? [Review] [29 refs]. Perit Dial Intl 27: S190-S195, 2007
9. Vonesh E, Snyder J, Foley R, Collins A: Mortality studies comparing peritoneal dialysis and hemodialysis: what do they tell us? Kidney Int 70:S3-S11, 2006
10. Mehrotra R, Chiu Y-W, Kalantar-Zadeh K, Bargman J, Vonesh E: Similar outcomes with hemodialysis and peritoneal dialysis in patients with end-stage renal disease. Arch Intern Med 171:110-118, 2010
11. Jaar BG, Coresh J, Plantinga LC, Fink NE, Klag MJ, Levey AS, Levin NW, Sadler JH, Kliger A, Powe NR: Comparing the risk for death with peritoneal dialysis and hemodialysis in a national cohort of patients with chronic kidney disease. Ann Intern Med 143:174-183, 2005
12. Davies SJ, Phillips L, Naish PF, Russell GI: Peritoneal glucose exposure and changes in membrane solute transport with time on peritoneal dialysis. J Am Soc Nephrol 12:1046-1051, 2001
13. McCafferty K, Fan S, Davenport A: Extracellular volume expansion, measured by multifrequency bioimpedance, does not help preserve residual renal function in peritoneal dialysis patients. Kidney Int 85:151-157, 2013
14. Szeto C-C, Kwan BC, Chow K-M, Chung S, Yu V, Cheng M-S, Leung C-B, Law M-C, Li PK: Predictors of residual renal function decline in patients undergoing continuous ambulatory peritoneal dialysis. Perit Dial Int doi: 10.3747/pdi.2013.00075, 2014
15. Johnson DW, Mudge DW, Sturtevant JM, Hawley CM, Campbell SB, Isbel NM, Hollett P: Predictors of decline of residual renal function in new peritoneal dialysis patients. Perit Dial Int 23:276-283, 2003
16. Perl J, Bargman JM: The importance of residual kidney function for patients on dialysis: a critical review. Am J Kidney Dis 53:1068-1081, 2009
17. Singhal MK, Bhaskaran S, Vidgen E, Bargman JM, Vas SI, Oreopoulos DG: Rate of decline of residual renal function in patients on continuous peritoneal dialysis and factors affecting it. Perit Dial Int 20:429-438, 2000
18. Hidaka H, Nakao T: Preservation of residual renal function and factors affecting its decline in patients on peritoneal dialysis. Nephrol 8:184-191, 2003
19. Traynor JP, Simpson K, Geddes CC, Deighan CJ, Fox JG: Early initiation of dialysis fails to prolong survival in patients with end-stage renal failure. J Am Soc Nephrol 13:2125-2132, 2002
20. Kazmi WH, Gilbertson DT, Obrador GT, Guo H, Pereira BJ, Collins AJ, Kausz AT: Effect of comorbidity on the increased mortality associated with early initiation of dialysis. Am J Kidney Dis 46:887-896, 2005
21. Vilar E, Wellsted D, Chandna SM, Greenwood RN, Farrington K: Residual renal function improves outcome in incremental haemodialysis despite reduced dialysis dose. Nephrol Dial Transplant 24:2502-2510, 2009
22. Bragg-Gresham JL, Fissell RB, Mason NA, Bailie GR, Gillespie BW, Wizemann V, Cruz JM, Akiba T, Kurokawa K, Ramirez S, Young EW: Diuretic use, residual renal function, and mortality among hemodialysis patients in the Dialysis Outcomes and Practice Pattern Study (DOPPS). Am J Kidney Dis 49:426-431, 2007
23. Shemin D, Bostom AG, Laliberty P, Dworkin LD: Residual renal function and mortality risk in hemodialysis patients. Am J Kidney Dis 38:85-90, 2001
24. Briet M, Schiffrin EL: Aldosterone: effects on the kidney and cardiovascular system. Nat Rev Nephrol 6:261-273, 2010
25. Navis G, de Jong P, Donker A, van der Hem G, de Zeeuw D: Diuretic effects of angiotensin-converting enzyme inhibition: comparison of low and liberal sodium diet in hypertensive patients. J Cardiovasc Pharmacol 9:743-748, 1987
26. Perret-Guillaume C, Joly L, Jankowski P, Benetos A: Benefits of the RAS blockade: clinical evidence before the ONTARGET study. J Hypertens 27:S3-S7, 2009
27. Villa L, Boor P, Konieczny A, Kunter U, Roeyen CRCv, Denecke B B, Gan L, Kupper MB, Hoffmann K, Eitner F F, Ostendorf T, Floege J: Effects and mechanisms of angiotensin II receptor blockade with telmisartan in a normotensive model of mesangioproliferative nephritis. Nephrol Dial Transplant 26:3131-3143, 2011
28. Karihaloo A: Anti-fibrosis therapy and diabetic nephropathy. Curr Diab Rep 12:414-422, 2012
29. Remuzzi A, Gagliardini E, Sangalli F, Bonomelli M, Piccinelli M, Benigni A, Remuzzi G: ACE inhibition reduces glomerulosclerosis and regenerates glomerular tissue in a model of progressive renal disease. Kidney Int 69:1124-1130, 2006
30. Gross O, Schulze-Lohoff E, Koepke ML, Beirowski B, Addicks K, Bloch W, Smyth N, Weber M: Antifibrotic, nephroprotective potential of ACE inhibitor vs AT1 antagonist in a murine model of renal fibrosis. Nephrol Dial Transplant 19:1716-1723, 2004
31. Palaniyappan A, Uwiera RR, Idikio H, Jugdutt BI: Comparison of vasopeptidase inhibitor omapatrilat and angiotensin receptor blocker candesartan on extracellular matrix, myeloperoxidase, cytokines, and ventricular remodeling during healing after reperfused myocardial infarction. Mol Cell Biochem 321:9-22, 2009
32. Fang W, Oreopoulos DG, Bargman JM: Use of ACE inhibitors or angiotensin receptor blockers and survival in patients on peritoneal dialysis. Nephrol Dial Transplant 23:3704-3710, 2008
33. Efrati S, Zaidenstein R, Dishy V, Beberashvili I, Sharist M, Averbukh Z, Golik A, Weissgarten J: ACE inhibitors and survival of hemodialysis patients. Am J Kidney Dis 40:1023-1029, 2002
34. Suzuki H, Kanno Y, Sugahara S, Okada H, Nakamoto H: Effects of an angiotensin II receptor blocker, valsartan, on residual renal function in patients on CAPD. Am J Kidney Dis 43:1056-1064, 2004
35. Li PK, Chow KM, Wong TY, Leung CB, Szeto CC: Effects of an angiotensin-converting enzyme inhibitor on residual renal function in patients receiving peritoneal dialysis. A randomized, controlled study. Ann Intern Med 139:105-112, 2003
36. Xydakis D, Papadogiannakis A, Sfakianaki M, Kostakis K, Stylianou K, Petrakis I, Ergini A, Voskarides K, Dafnis E: Residual renal function in hemodialysis patients: the role of Angiotensin-converting enzyme inhibitor in its preservation. ISRN Nephrol 2013:184527, 2013
37. Kjaergaard KD, Peters CD, Jespersen B, Tietze IN, Madsen JK, Pedersen BB, Novosel MK, Laursen KS, Bibby BM, Strandhave C, Jensen JD: Angiotensin blockade and progressive loss of kidney function in hemodialysis patients: a randomized controlled trial. Am J Kidney Dis doi: 10.1053/j.ajkd.2014.05.011, 2014
38. Peters CD, Kjaergaard KD, Jespersen B, Christensen KL, Jensen JD: Renal and cardiovascular effects of irbesartan in dialysis patients-a randomized controlled trial protocol (SAFIR study). Dan Med J 60:A4602, 2013
39. Itoh Y, Fujikawa T, Toya Y, Mitsuhashi H, Kobayashi N, Ohnishi T, Tamura K, Hirawa N, Yasuda G, Umemura S: Effect of renin-angiotensin system inhibitor on residual glomerular filtration rate in hemodialysis patients. Ther Apher Dial 16:554-559, 2012
40. Peters H, Ruckert M, Gaedeke J, Liefeldt L, Ketteler M, Sharma AM, Neumayer HH: Angiotensin-converting enzyme inhibition but not beta-adrenergic blockade limits transforming growth factor-beta overexpression in acute normotensive anti-thy1 glomerulonephritis. J Hypertens 21:771-780, 2003
41. Guney I, Selcuk NY, Altintepe L, Atalay H, Basarali MK, Buyukbas S: Antifibrotic effects of aldosterone receptor blocker (spironolactone) in patients with chronic kidney disease. Ren Fail 31:779-784, 2009
42. Gamboa JL, Pretorius M, Todd-Tzanetos DR, Luther JM, Yu C, Ikizler TA, Brown NJ: Comparative effects of angiotensin-converting enzyme inhibition and angiotensin-receptor blockade on inflammation during hemodialysis. J Am Soc Nephrol 23:334-342, 2012
43. Tien KJ, Lin ZZ, Chio CC, Wang JJ, Chu CC, Sun YM, Kan WC, Chien CC: Epidemiology and mortality of new-onset diabetes after dialysis: Taiwan national cohort study. Diabetes Care 36:3027-3032, 2013
44. Lee CC, Sun CY, Wu MS: Long-term modality-related mortality analysis in incident dialysis patients. Perit Dial Int 29:182-190, 2009
45. Weinhandl ED, Foley RN, Gilbertson DT, Arneson TJ, Snyder JJ, Collins AJ: Propensity-matched mortality comparison of incident hemodialysis and peritoneal dialysis patients. J Am Soc Nephrol 21:499-506, 2010
46. Szeto CC, Chow KM, Kwan BC, Chung KY, Leung CB, Li PK: New-onset hyperglycemia in nondiabetic chinese patients started on peritoneal dialysis. Am J Kidney Dis 49:524-532, 2007
47. de Boer IH, Sun W, Cleary PA, Lachin JM, Molitch ME, Steffes MW, Zinman B: Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes. N Engl J Med 365:2366-2376, 2011
48. Singh AK, Mo W, Dunea G, Arruda JA: Effect of glycated proteins on the matrix of glomerular epithelial cells. J Am Soc Nephrol 9:802-810, 1998
49. Astrup AS, Tarnow L, Pietraszek L, Schalkwijk CG, Stehouwer CD, Parving HH, Rossing P: Markers of endothelial dysfunction and inflammation in type 1 diabetic patients with or without diabetic nephropathy followed for 10 years: association with mortality and decline of glomerular filtration rate. Diabetes Care 31:1170-1176, 2008
50. Navarro-Gonzalez JF, Mora-Fernandez C: The role of inflammatory cytokines in diabetic nephropathy. J Am Soc Nephrol 19:433-442, 2008
51. Sowers JR, Raij L, Jialal I, Egan BM, Ofili EO, Samuel R, Zappe DH, Purkayastha D, Deedwania PC: Angiotensin receptor blocker/diuretic combination preserves insulin responses in obese hypertensives. J Hypertens 28:1761-1769, 2010
52. Andraws R, Brown DL: Effect of inhibition of the renin-angiotensin system on development of type 2 diabetes mellitus (meta-analysis of randomized trials). Am J Cardiol 99:1006-1012, 2007
53. Kramer HJ, Saranathan A, Luke A, Durazo-Arvizu RA, Guichan C, Hou S, Cooper R: Increasing body mass index and obesity in the incident ESRD population. J Am Soc Nephrol 17:1453-1459, 2006
54. Thethi T, Kamiyama M, Kobori H: The link between the renin-angiotensin-aldosterone system and renal injury in obesity and the metabolic syndrome. Curr Hypertens Rep 14:160-169, 2012
55. Hunley TE, Ma LJ, Kon V: Scope and mechanisms of obesity-related renal disease. Curr Opin Nephrol Hypertens 19:227-234, 2010
56. Johnson DW: What is the optimal fat mass in peritoneal dialysis patients? [Review] [42 refs]. Perit Dial Int 27:S250-S254, 2007
57. Kopple JD, Zhu X, Lew NL, Lowrie EG: Body weight-for-height relationships predict mortality in maintenance hemodialysis patients. Kidney Int 56:1136-1148, 1999
58. Navarro-Diaz M, Serra A, Lopez D, Granada M, Bayes B, Romero R: Obesity, inflammation, and kidney disease. Kidney Int Suppl 111:S15-S18, 2008
59. Nasrallah MP, Ziyadeh FN: Overview of the physiology and pathophysiology of leptin with special emphasis on its role in the kidney. Semin Nephrol 33:54-65, 2013
60. Morales E, Praga M: The effect of weight loss in obesity and chronic kidney disease. Curr Hypertens Rep 14:170-176, 2012
61. Alexander JW, Goodman HR, Hawver LR, Cardi MA: Improvement and stabilization of chronic kidney disease after gastric bypass. Surg Obes Relat Dis 5:237-241, 2009
62. Epstein M, Campese VM: Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors on renal function. Am J Kidney Dis 45:2-14, 2005
63. Yoshimura A, Inui K, Nemoto T, Uda S, Sugenoya Y, Watanabe S, Yokota N, Taira T, Iwasaki S, Ideura T: Simvastatin suppresses glomerular cell proliferation and macrophage infiltration in rats with mesangial proliferative nephritis. J Am Soc Nephrol 9:2027-2039, 1998
64. Haynes R, Lewis D, Emberson J, Reith C, Agodoa L, Cass AC, Craig J, de Zeeuw D, Feldt-Rasmussen B, Fellström B, Levin A, Wheeler DC, Walker R, Herrington WG, Baigent C, Landray MJ, Group ftSC: Effects of lowering LDL cholesterol on progression of kidney disease. J Am Soc Nephrol doi: 10.1681/asn.2013090965, 2014
65. Sandhu S, Wiebe N, Fried LF, Tonelli M: Statins for improving renal outcomes: a meta-analysis. J Am Soc Nephrol 17:2006-2016, 2006
66. Han SH, Kang EW, Yoon SJ, Yoon HS, Lee HC, Yoo TH, Choi KH, Han DS, Kang SW: Combined vascular effects of HMG-CoA reductase inhibitor and angiotensin receptor blocker in non-diabetic patients undergoing peritoneal dialysis. Nephrol Dial Transplant 26:3722-3728, 2011
67. Liao CT, Shiao CC, Huang JW, Hung KY, Chuang HF, Chen YM, Wu KD, Tsai TJ: Predictors of faster decline of residual renal function in Taiwanese peritoneal dialysis patients. Perit Dial Int 28:S191-S195, 2008
68. Daugirdas JT, Greene T, Rocco MV, Kaysen GA, Depner TA, Levin NW, Chertow GM, Ornt DB, Raimann JG, Larive B, Kliger AS, Group FHNT: Effect of frequent hemodialysis on residual kidney function. Kidney Int 83: 949-958, 2013
69. Liu S, Diao Z, Zhang D, Ding J, Cui W, Liu W: Preservation of residual renal function by not removing water in new hemodialysis patients: a randomized, controlled study. Int Urol Nephrol 46:83-90, 2014
70. Medcalf JF, Harris KP, Walls J: Role of diuretics in the preservation of residual renal function in patients on continuous ambulatory peritoneal dialysis. Kidney Int 59:1128-1133, 2001
71. Lemes HP, Araujo S, Nascimento D, Cunha D, Garcia C, Queiroz V, Ferreira-Filho SR: Use of small doses of furosemide in chronic kidney disease patients with residual renal function undergoing hemodialysis. Clin Exp Nephrol 15:554-559, 2011
72. Hartmann J, Fricke H, Schiffl H: Biocompatible membranes preserve residual renal function in patients undergoing regular hemodialysis. Am J Kidney Dis 30:366-373, 1997
73. McCarthy JT, Jenson BM, Squillace DP, Williams AW: Improved preservation of residual renal function in chronic hemodialysis patients using polysulfone dialyzers. Am J Kidney Dis 29:576-583, 1997
74. Kim S, Oh J, Chung W, Ahn C, Kim SG, Oh KH: Benefits of biocompatible PD fluid for preservation of residual renal function in incident CAPD patients: a 1-year study. Nephrol Dial Transplant 24:2899-2908, 2009
75. Lui SL, Yung S, Yim A, Wong KM, Tong KL, Wong KS, Li CS, Au TC, Lo WK, Ho YW, Ng F, Tang C, Chan TM: A combination of biocompatible peritoneal dialysis solutions and residual renal function, peritoneal transport, and inflammation markers: a randomized clinical trial. Am J Kidney Dis 60:966-975, 2012
76. Fan SL, Pile T, Punzalan S, Raftery MJ, Yaqoob MM: Randomized controlled study of biocompatible peritoneal dialysis solutions: effect on residual renal function. Kidney Int 73:200-206, 2008
77. Haag-Weber M, Kramer R, Haake R, Islam MS, Prischl F, Haug U, Nabut JL, Deppisch R: Low-GDP fluid (Gambrosol trio) attenuates decline of residual renal function in PD patients: a prospective randomized study. Nephrol Dial Transplant 25:2288-2296, 2010
78. Schiffl H, Lang SM, Fischer R: Ultrapure dialysis fluid slows loss of residual renal function in new dialysis patients. Nephrol Dial Transplant 17:1814-1818, 2002
79. McKane W, Chandna SM, Tattersall JE, Greenwood RN, Farrington K: Identical decline of residual renal function in high-flux biocompatible hemodialysis and CAPD. Kidney Int 61:256-265, 2002
80. Ravani P, Malberti F, Tripepi G, Pecchini P, Cutrupi S, Pizzini P, Mallamaci F, Zoccali C: Vitamin D levels and patient outcome in chronic kidney disease. Kidney Int 75:88-95, 2009
81. Li YC: Vitamin D: roles in renal and cardiovascular protection. Curr Opin Nephrol Hypertens 21:72-79, 2012
82. Janousek R, Krajina A, Peregrin J, Dusilova-Sulkova S, Renc O, Hajek J, Dvorak K, Fixa P, Cermakova E: Effect of intravascular iodinated contrast media on natural course of end-stage renal disease progression in hemodialysis patients: a prospective study. Cardiovasc Intervent Radiol 33:61-66, 2010
83. Feldman L, Shani M, Efrati S, Beberashvili I, Yakov-Hai I, Abramov E, Sinuani I, Rosenberg R, Weissgarten J: N-acetylcysteine improves residual renal function in peritoneal dialysis patients: a pilot study. Perit Dial Int 31:545-550, 2011
84. Feldman L, Shani M, Sinuani I, Beberashvili I, Weissgarten J: N-acetylcysteine may improve residual renal function in hemodialysis patients: a pilot study. Hemodial Int 16:512-516, 2012
85. Shemin D, Maaz D, St Pierre D, Kahn SI, Chazan JA: Effect of aminoglycoside use on residual renal function in peritoneal dialysis patients. Am J Kidney Dis 34:14-20, 1999
86. Badve SV, Hawley CM, McDonald SP, Brown FG, Boudville NC, Wiggins KJ, Bannister KM, Johnson DW: Use of aminoglycosides for peritoneal dialysis-associated peritonitis does not affect residual renal function. Nephrol Dial Transplant 27:381-387, 2012
87. Li PK, Szeto CC, Piraino B, Bernardini J, Figueiredo AE, Gupta A, Johnson DW, Kuijper EJ, Lye WC, Salzer W, Schaefer F, Struijk DG: Peritoneal dialysis-related infections recommendations: 2010 update. Perit Dial Int 30:393-423, 2010